Latest news
Full year results 2024: portfolio makes good progress in challenging conditions
Commercial and financial developments during the year mean our portfolio is now a mix of companies at different stages of maturity. There was also strong technical progress across the portfolio. Despite the difficult funding environment, four companies raised money during the period and post the year end. We continued to strengthen management teams.
Read moreWatch: Frontier CEO Neil Crabb on full year results, portfolio progress and our fundraising
Neil takes Proactive’s Stephen Gunnion through the company’s annual results, the £3 million placing and subscription, as well as a separate offer to retail investors. Despite challenging financial markets, the company saw a modest gain in portfolio value and reduced losses, signalling resilience and growth potential.
Read moreWatch: The Vaccine Group CEO Dr Jeremy Salt on £400,000 Innovate UK grant for animal health
Dr Jeremy Salt talks about how The Vaccine Group will work with the Animal and Plant Health Agency to develop novel vaccines to combat cattle diseases. He also touches on future developments.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesDeakinBio
DeakinBio has developed a technology, termed BioSintering®, to produce advanced bio-based materials from organic waste such as chickpea broth or algae, along with widely available inorganic powders such as crushed limestone.
Learn more
